– ISRAEL, Kadima – Magenta Medical today announced the appointment of Bill Hoffman to its Board of Directors.
“Bill Hoffman is a widely respected and accomplished leader in the MedTech industry. The company is certain to benefit from his experience and insights as it looks to achieve its upcoming clinical milestones and future commercial goals,” said CEO, Dr. David Israeli.
About Bill Hoffman
Bill Hoffman currently serves as a member of the board of directors of Inari Medical, where he was CEO from 2015 until 2022. In May 2020, he led the company to a successful IPO. Prior to Inari Medical, Mr. Hoffman served as CEO of Visualase, Inc., and VP of Sales at FoxHollow Technologies, acquired by Medtronic and ev3, respectively.
“Magenta is developing a next-generation temporary mechanical circulatory support system that addresses the important shortcomings of current systems around insertion size and flow. The team is mission-driven, and I love their commitment to treat underserved populations, improve patient outcomes, and save lives,” said Bill Hoffman.
About Magenta Medical
Magenta Medical Ltd. is a privately held company dedicated to the development of miniaturized blood pumps intended to provide minimally invasive support to the native heart during acute episodes of dysfunction that could lead to dangerously low blood pressure and compromised perfusion of vital organs. Magenta’s Elevate™ percutaneous Left Ventricular Assist Device (pLVAD) is currently in clinical trials to be evaluated for at least two indications: patients undergoing high-risk percutaneous coronary interventions (HR-PCI) and patients with cardiogenic shock.
For more, visit https://magentamed.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
